Last updated: July 19, 2026
- Asserted patents: patent numbers listed in the complaint and any subsequent amendment.
- ANDA/NDA linkage: the specific drug (active ingredient, dosage form, strength) and the NDA to which Alvogen’s application referred.
- Paragraph IV certifications: which patents were alleged invalid and/or not infringed, and the certifications used.
- Relief requested: declaratory judgment scope and any request for injunction pending FDA approval.
- Procedural events: claim construction (Markman), summary judgment, any PTO reexamination outcomes tied to the asserted claims, and dispositive motions.
- Disposition: final judgment date, whether the case settled, and the key economic terms if settlement affected launch timing (dates, design-arounds, license scope).
What patents were asserted in Sanofi-Aventis v. Alvogen Pine Brook LLC under Hatch-Waxman?
What a complete “patent estate” section must contain
- Patent numbers asserted (and asserted claims ranges).
- Patent owners/assignees (Sanofi vs. affiliates or licensees).
- Status of patents during the case (expiration, terminal disclaimer, PTA).
- Whether litigation involved formulation, method-of-use, or manufacturing-process claims.
Why this cannot be completed
No asserted-patent list is provided in the request, and the case number alone (1:16-cv-01300) is not sufficient to reliably identify the exact Orange Book patents without access to the docket documents (complaint and Patent Litigations order records).
How did the court handle claim construction, infringement, and invalidity in Sanofi v. Alvogen (1:16-cv-01300)?
A litigation analysis typically breaks into:
- Claim construction: court’s constructions for key limitations.
- Infringement analysis: claim charts tying the ANDA label/product to each limitation.
- Validity analysis: grounds such as anticipation, obviousness, lack of written description/enablement, indefiniteness, and prosecution history estoppel.
Why this cannot be completed
The request does not include the claim-construction order, any summary-judgment or trial verdict, or the final judgment. Without those, the outcome of infringement/invalidity cannot be stated.
Did the case settle, and what launch/entry terms were agreed for Alvogen’s ANDA?
A settlement-driven Hatch-Waxman story usually includes:
- Settlement date.
- “Carve-out” or covenant terms: permitted design-around(s).
- No-AG settlement triggers: approval timing, exclusivity carve-outs, or permitted sales windows.
- Dismissal with/without prejudice: and whether it was accompanied by a consent injunction (or a covenant not to sue).
Why this cannot be completed
The request does not include the settlement agreement terms or any docket entries that show dismissal/consent judgment.
What is the Orange Book status for the Sanofi drug at issue in 1:16-cv-01300?
To answer Orange Book status, a complete entry must show:
- Reference listed drug (RLD) name and strength(s).
- Listed patents, expiration dates, and statutory exclusivities relevant to the RLD.
- Whether the asserted patents were composition, method-of-use, or formulation patents.
- Any “new use” or “switch” listings impacting paragraph IV timing.
Why this cannot be completed
The RLD and the asserted Orange Book patents are not specified in the request.
When did exclusivity end for the Sanofi product in 1:16-cv-01300, and when could Alvogen launch?
A credible exclusivity timeline must include:
- Patent expiration and any terminal disclaimer adjustments.
- Statutory exclusivity periods (NCE exclusivity, pediatric exclusivity) if applicable.
- Any settlement-driven launch dates.
- If relevant, 180-day exclusivity triggers and whether it was forfeited or triggered by first-filer status.
Why this cannot be completed
No RLD identification or patent/entry dates are provided.
Which competitors challenged Sanofi patents around this same time period and for the same ANDA reference product?
A robust landscape section typically identifies:
- Other ANDA filers (e.g., Teva, Mylan, Hikma, Accord, Apotex, Sandoz) with co-pending litigations.
- Whether there were parallel actions in other districts or before the same judge.
- Shared patents asserted across actions and different design-arounds.
Why this cannot be completed
The specific drug and patent set are not provided, so the litigation map cannot be reconstructed without risk of inaccuracy.
How strong was Sanofi’s patent position in 1:16-cv-01300 based on the court’s rulings?
A litigation-strength assessment requires:
- Whether the court denied motions to dismiss or for summary judgment.
- Claim-construction outcomes favoring infringement or invalidity arguments.
- Whether the court found non-infringement due to label carve-outs or product differences.
- Any validity survival after summary judgment.
Why this cannot be completed
The court’s substantive rulings are not included in the request.
Key docket and outcome metrics that drive business decisions
A business-facing litigation dashboard for this case must show:
- Filed date, amended complaint date(s), and any stipulations.
- Scheduling order milestones (Markman date, summary judgment deadlines).
- Dispositive decision dates.
- Settlement/dismissal dates and stated reasons.
- Injunction scope and whether FDA approval could proceed.
Why this cannot be completed
No docket timeline entries are provided.
Key Takeaways
- The case caption and docket number identify the matter as Sanofi-Aventis U.S. LLC v. Alvogen Pine Brook LLC (1:16-cv-01300), but they do not provide enough case-specific information to produce a complete and accurate litigation summary or patent/IP analysis.
- A complete summary requires the asserted-patent list, procedural rulings, and final disposition (judgment or settlement terms). Those inputs are not present.
FAQs
- What does 1:16-cv-01300 indicate about the statutory basis in Sanofi v. Alvogen?
- How do Paragraph IV certifications typically shape the issues in Sanofi-Aventis v. Alvogen Pine Brook LLC?
- What procedural events usually occur after filing in Hatch-Waxman cases like this one (Markman, summary judgment)?
- How do settlement terms in Hatch-Waxman actions affect ANDA launch timing and design-arounds?
- What kinds of patents (composition, method-of-use, formulation) most often generate litigation in Sanofi Orange Book listings?
References
No sources were cited because the request does not include the docket content, court orders, asserted patents, or final judgment necessary to ground a litigation summary.
